$140 Million is the total value of New Leaf Venture Partners, L.L.C.'s 15 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 21.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VSAR | VERSARTIS INC | $30,384,000 | +21.6% | 2,039,223 | 0.0% | 21.76% | +21.0% | |
| EDGE | EDGE THERAPEUTICS INC | $29,311,000 | +20.1% | 2,344,868 | 0.0% | 20.99% | +19.5% | |
| OXFD | OXFORD IMMUNOTEC GLOBAL PLC | $20,594,000 | +19.0% | 1,377,497 | 0.0% | 14.75% | +18.4% | |
| WVE | Sell | WAVE LIFE SCIENCES LTD | $17,213,000 | -32.4% | 658,259 | -16.1% | 12.33% | -32.7% |
| CRSP | New | CRISPR THERAPEUTICS AGnamen akt | $11,882,000 | – | 586,475 | +100.0% | 8.51% | – |
| DMTX | DIMENSION THERAPEUTICS INC | $8,958,000 | -45.6% | 2,059,283 | 0.0% | 6.42% | -45.8% | |
| SAGE | Sell | SAGE THERAPEUTICS INC | $5,827,000 | -4.6% | 114,123 | -14.0% | 4.17% | -5.1% |
| DERM | Sell | DERMIRA INC | $5,394,000 | -17.8% | 177,844 | -8.3% | 3.86% | -18.2% |
| ALDR | Sell | ALDER BIOPHARMACEUTICALS INC | $4,751,000 | -37.2% | 228,428 | -1.1% | 3.40% | -37.5% |
| AVEO | AVEO PHARMACEUTICALS INC | $1,399,000 | -39.3% | 2,590,673 | 0.0% | 1.00% | -39.6% | |
| VTGN | VISTAGEN THERAPEUTICS INC | $1,317,000 | -11.8% | 352,950 | 0.0% | 0.94% | -12.3% | |
| DVAX | Sell | DYNAVAX TECHNOLOGIES CORP | $1,013,000 | -75.9% | 256,381 | -36.0% | 0.73% | -76.0% |
| EVAR | New | LOMBARD MEDICAL INC | $643,000 | – | 1,072,634 | +100.0% | 0.46% | – |
| Buy | TRILLIUM THERAPEUTICS INC | $547,000 | -54.1% | 96,759 | +19.8% | 0.39% | -54.4% | |
| ITEK | Buy | INOTEK PHARMACEUTICALS CORP | $380,000 | -20.3% | 62,300 | +23.9% | 0.27% | -20.7% |
| ADAP | Exit | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $0 | – | -55,008 | -100.0% | -0.28% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DECIPHERA THERAPEUTICS INC | 25 | Q3 2023 | 44.4% |
| CHIMERIX INC | 25 | Q1 2023 | 20.9% |
| SIERRA ONCOLOGY INC | 22 | Q2 2022 | 14.9% |
| ARVINAS INC | 21 | Q3 2023 | 44.8% |
| CRINETICS PHARMACEUTICALS INC | 21 | Q3 2023 | 11.4% |
| OBSEVA SA | 20 | Q4 2021 | 8.5% |
| AVROBIO INC | 20 | Q1 2023 | 1.7% |
| HARPOON THERAPEUTICS INC | 19 | Q3 2023 | 20.0% |
| ALECTOR INC | 19 | Q3 2023 | 4.6% |
| ITERUM THERAPEUTICS PLC | 18 | Q3 2022 | 3.8% |
View New Leaf Venture Partners, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-06 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-09 |
| 13F-HR | 2022-05-06 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
View New Leaf Venture Partners, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.